<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014111213421N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2015-01-10</date_registration>
      <primary_sponsor>Urmia University of Medical Sciences</primary_sponsor>
      <public_title>Prednisolone on pregnancy outcomes</public_title>
      <acronym>prednizolone and microinjection</acronym>
      <scientific_title>Effects of Prednisolone on pregnancy outcomes among infertile patients undergoing ‎‎Intra Cytoplasmic Sperm Injection (ICSI)‎</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2010-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>248</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/13277</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: -.</study_design>
      <phase>N/A</phase>
      <hc_freetext>infertility.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Patients who candidate for microinjection (ICSI), underwent for induction of ovulation, underwent by long protocol in the beginning of cycle. Determination of uterus depth was done for all patients. For all of patients were given  100 mg/12 hrs Doxycycline for 10 days and 1 mg daily Folic acid from the previous cycle, Contraceptive pills daily started on the second day of their menses and continued for 21 day. 50 line of insulin syringe Superfact (Buserelin) was injected sc. 6 days before menstruation. After end of 21 contraception pill consumption, on the second day of menstral cycle the injected dose of Superfact GnRH Antagonist  (Buserelin) was reduced to half. First, we started gonadotropin (Gonal.F) S.C from second days, after 1 week , Gonal.F and menogone to given suitable follicles. Dose of gonadotropin was determined base on age, FSH level , amount of antral folicule and history of IVF. The size of the follicles and endometrial thickness was monitored by transvaginal sonography. Once at least 3 follicles reached the size of 18 mm, 10000 units hCG (FERRING-Germany) was injected to the patient. Ovum pick up was done 34 hours after the injection by transvaginal sonography under spinal or light general anesthesia were extracted. After 72 hours ,embryos were transferred in distance 1cm up to foundus of uterus. Same sequential media (GII series, VitrolifeTM ; Colorado, USA) was used for all embryo culturing. Embryo scoring was done according to zonal thickness, cytoplasm fragmentation, blastomeres number, and morphology. The clinician also made sure that the endometrium has three lines and its thickness is 8-10 mm.  for luteal phase support 100 mg progesterone  IM daily were given from ovum pick up day  , detecting  receiving positive β HCG results and detecting of fetal heart by sonography  , respectively  to 11 weeks of pregnancy. Intervention 2: Intervention Group also followed the same procedure as control groups and the same medications were used. In addition, 20 mg daily prednisolone was given to all Intervention Group, One day before the emberyo transfer, 20 mg daily prednisolone were used for one week. Prednisolone’s dose reduced to 10 mg daily for the second week and 5 mg daily in the last 2 days and then was stopped. One tablet Ranitidine also was used to prevent any possible stomach and intestinal discomfort in the morning.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fariba Nanbakhsh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Urmia ,Kashani Street , Health Center No 6,Room NO 42</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0443445138</zip>
        <telephone>+98 44 3344 5138</telephone>
        <email>-</email>
        <affiliation>Reproductive Health Research Center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fariba Nanbakhsh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Urmia,Kashani Street,Motahri Hospital</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>04433445138</zip>
        <telephone>+98 44 3344 5138</telephone>
        <email>f.nanbakhsh@umsu.ac.ir</email>
        <affiliation>Reproductive Health Research Center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>i nclusion criteria: having infertility;FSH serum levels lower than 10 ,age of lower than 42 years &#13;
exclusion criteria: having asthma;  systemic disorders; gastrointestinal disorders</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Patients who candidate for microinjection (ICSI), underwent for induction of ovulation, underwent by long protocol in the beginning of cycle. Determination of uterus depth was done for all patients. For all of patients were given  100 mg/12 hrs Doxycycline for 10 days and 1 mg daily Folic acid from the previous cycle, Contraceptive pills daily started on the second day of their menses and continued for 21 day. 50 line of insulin syringe Superfact (Buserelin) was injected sc. 6 days before menstruation. After end of 21 contraception pill consumption, on the second day of menstral cycle the injected dose of Superfact GnRH Antagonist  (Buserelin) was reduced to half. First, we started gonadotropin (Gonal.F) S.C from second days, after 1 week , Gonal.F and menogone to given suitable follicles. Dose of gonadotropin was determined base on age, FSH level , amount of antral folicule and history of IVF. The size of the follicles and endometrial thickness was monitored by transvaginal sonography. Once at least 3 follicles reached the size of 18 mm, 10000 units hCG (FERRING-Germany) was injected to the patient. Ovum pick up was done 34 hours after the injection by transvaginal sonography under spinal or light general anesthesia were extracted. After 72 hours ,embryos were transferred in distance 1cm up to foundus of uterus. Same sequential media (GII series, VitrolifeTM ; Colorado, USA) was used for all embryo culturing. Embryo scoring was done according to zonal thickness, cytoplasm fragmentation, blastomeres number, and morphology. The clinician also made sure that the endometrium has three lines and its thickness is 8-10 mm.  for luteal phase support 100 mg progesterone  IM daily were given from ovum pick up day  , detecting  receiving positive β HCG results and detecting of fetal heart by sonography  , respectively  to 11 weeks of pregnancy.</i_keyword>
      <i_keyword>Intervention Group also followed the same procedure as control groups and the same medications were used. In addition, 20 mg daily prednisolone was given to all Intervention Group, One day before the emberyo transfer, 20 mg daily prednisolone were used for one week. Prednisolone’s dose reduced to 10 mg daily for the second week and 5 mg daily in the last 2 days and then was stopped. One tablet Ranitidine also was used to prevent any possible stomach and intestinal discomfort in the morning.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Abortion. Timepoint: until 20 weeks. Method of measurement: observation.</prim_outcome>
      <prim_outcome>Intra uterus pregnancy. Timepoint: 12,20 weeks. Method of measurement: sonography.</prim_outcome>
      <prim_outcome>Chemical pregnancy. Timepoint: 6 weeks. Method of measurement: BHCG mesuring.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>None. Timepoint: none. Method of measurement: none.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Urmia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-09-23</approval_date>
        <contact_name>Urmia University of Medical Sciences</contact_name>
        <contact_address>Urmia,  Urmia University of Medical Sciences Urmia  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
